Oxurion NV
ISIN: BE0003846632 | Ticker: OXUR | LEI: 549300VWY8KVDFKLDM59
Country: Belgium
Oxurion is on a mission to transform the treatment of retinal disorders, including the development of THR-149, its novel therapeutic for the treatment of DME.
Oxurion is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people worldwide.
Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA, and is listed on Euronext Brussels under the symbol OXUR.
1991
Served areaWorldwide
HeadquartersGaston Geenslaan 1, 3001 Leuven, Vlaams-Brabant – Belgium
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 34,284,000.00 | 18,876,000.00 | 11,993,000.00 |
| Noncurrent Assets | N/A | 7,230,000.00 | 5,467,000.00 | 4,887,000.00 |
| Property Plant And Equipment | N/A | 230,000.00 | 120,000.00 | 99,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 2,127,000.00 | 1,000,000.00 | 0.00 |
| Other Noncurrent Nonfinancial Assets | N/A | 3,708,000.00 | 4,000,000.00 | 3,785,000.00 |
| Other Noncurrent Assets | N/A | 96,000.00 | 95,000.00 | 40,000.00 |
| Current Assets | N/A | 27,054,000.00 | 13,409,000.00 | 7,106,000.00 |
| Inventories | N/A | N/A | 60,000.00 | 5,000.00 |
| Other Current Financial Assets | N/A | 288,000.00 | 247,000.00 | N/A |
| Cash and cash equivalents | 42,492,000.00 | 24,511,000.00 | 9,740,000.00 | 3,496,000.00 |
| Shortterm Deposits Not Classified As Cash Equivalents | N/A | N/A | 247,000.00 | 95,000.00 |
| Equity And Liabilities | N/A | 34,284,000.00 | 18,876,000.00 | 11,993,000.00 |
| Equity | 53,306,000.00 | 25,048,000.00 | -1,108,000.00 | -4,583,000.00 |
| Issued Capital | N/A | 44,913,000.00 | 46,029,000.00 | 65,443,000.00 |
| Retained Earnings | N/A | -12,561,000.00 | -41,719,000.00 | -73,404,000.00 |
| Share Premium | N/A | 0.00 | 234,000.00 | 250,000.00 |
| Other Reserves | N/A | -6,133,000.00 | -5,266,000.00 | N/A |
| Equity Attributable To Owners Of Parent | N/A | 25,180,000.00 | -1,078,000.00 | -4,583,000.00 |
| Noncontrolling Interests | N/A | -132,000.00 | -30,000.00 | 0.00 |
| Noncurrent Liabilities | N/A | 1,543,000.00 | 9,071,000.00 | 4,227,000.00 |
| Noncurrent Recognised Liabilities Defined Benefit Plan | N/A | 1,096,000.00 | 594,000.00 | 159,000.00 |
| Noncurrent Portion Of Noncurrent Loans Received | N/A | 0.00 | 8,433,000.00 | N/A |
| Noncurrent Portion Of Noncurrent Bonds Issued | N/A | N/A | 8,433,000.00 | 3,235,000.00 |
| Current Liabilities | N/A | 7,693,000.00 | 10,913,000.00 | 12,349,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | N/A | 4,979,000.00 | 5,040,000.00 |
| Other Current Nonfinancial Liabilities | N/A | 2,667,000.00 | 2,312,000.00 | N/A |
| Other Current Liabilities | N/A | N/A | 2,312,000.00 | 3,361,000.00 |
| Current Loans Received And Current Portion Of Noncurrent Loans Received | N/A | 0.00 | 3,401,000.00 | N/A |
| Current Bonds Issued And Current Portion Of Noncurrent Bonds Issued | N/A | N/A | 3,401,000.00 | 3,809,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 2,078,000.00 | 1,128,000.00 | 595,000.00 |
| Revenue From Royalties | 78,000.00 | 161,000.00 | N/A |
| Profit Loss From Operating Activities | -28,620,000.00 | -28,495,000.00 | -22,946,000.00 |
| Finance Income | 468,000.00 | 171,000.00 | 639,000.00 |
| Finance Costs | 408,000.00 | 1,268,000.00 | 9,379,000.00 |
| Impairment Loss Impairment Gain And Reversal Of Impairment Loss Determined In Accordance With I F R S9 | 125,000.00 | 1,127,000.00 | N/A |
| Profit Loss Before Tax | -28,560,000.00 | -29,592,000.00 | -31,686,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 3,000.00 | 7,000.00 |
| Profit (loss) | -28,560,000.00 | -29,595,000.00 | -31,693,000.00 |
| Profit Loss Attributable To Owners Of Parent | -28,012,000.00 | -29,158,000.00 | -31,685,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | -548,000.00 | -437,000.00 | -8,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -28,560,000.00 | -29,595,000.00 | -31,693,000.00 |
| Adjustments For Finance Costs | N/A | 408,000.00 | 896,000.00 | 1,555,000.00 |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | N/A | 801,000.00 | 629,000.00 | N/A |
| Adjustments For Provisions | N/A | 0.00 | 64,000.00 | -75,000.00 |
| Adjustments For Sharebased Payments | N/A | 458,000.00 | 1,107,000.00 | 933,000.00 |
| Adjustments For Fair Value Gains Losses | N/A | 0.00 | 372,000.00 | 7,388,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -27,079,000.00 | -26,978,000.00 | -19,379,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 35,000.00 | 394,000.00 | 18,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 119,000.00 | 32,000.00 | 59,000.00 |
| Interest Received Classified As Investing Activities | N/A | -6,000.00 | 9,000.00 | 5,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 10,064,000.00 | 407,000.00 | 111,000.00 |
| Proceeds From Changes In Ownership Interests In Subsidiaries | N/A | N/A | 86,000.00 | 0.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 0.00 | 11,150,000.00 | N/A |
| Repayments Of Borrowings Classified As Financing Activities | N/A | N/A | 0.00 | 3,605,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 903,000.00 | 599,000.00 | 294,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 12,000.00 | 186,000.00 | 642,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | 0.00 | -20,000.00 | -7,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -931,000.00 | 11,778,000.00 | 13,001,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -35,000.00 | 22,000.00 | 23,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -17,946,000.00 | -14,793,000.00 | -6,267,000.00 |
| Cash and cash equivalents | 42,492,000.00 | 24,511,000.00 | 9,740,000.00 | 3,496,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 07.03.22 | Bareldam SA | Close relation | Buy | EUR 1,700,000.00 |
| 30.09.21 | Lavinia D. Clay 2009 Revocable Trust | Close relation | Other | EUR 5,601,002.52 |
BE0003846632
LEI549300VWY8KVDFKLDM59
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.